Mycenax Biotech Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 159.26 million compared to TWD 154.43 million a year ago. Net loss was TWD 172.97 million compared to TWD 79.23 million a year ago. Basic loss per share was TWD 1.12 compared to TWD 0.52 a year ago. Diluted loss per share was TWD 1.12 compared to TWD 0.52 a year ago.
For the nine months, sales was TWD 536.41 million compared to TWD 553.38 million a year ago. Net loss was TWD 271.09 million compared to TWD 33.95 million a year ago. Basic loss per share was TWD 1.76 compared to TWD 0.23 a year ago. Diluted loss per share was TWD 1.76 compared to TWD 0.23 a year ago.